Juzina (Sitagliptin)

Sitagliptin blocks the enzyme dipeptidyl peptidase-4, which normally breaks down the incretin hormones GLP-1 and GIP. By inhibiting DPP-4, the drug prolongs the action of these hormones, leading to glucose‑dependent insulin release and decreased glucagon, thereby improving glycemic control.

The prescribed dose of Juzina is determined by the treating physician based on the patient’s renal function, glycemic targets, and any concomitant antidiabetic medications. Dosage adjustments may be required for patients with impaired kidney function.

The safety of sitagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Juzina product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin offers glucose‑dependent insulin stimulation, resulting in a lower risk of hypoglycemia. Unlike metformin, it does not affect gastrointestinal absorption and can be used as add‑on therapy when metformin alone does not achieve target glycemic control.

Juzina tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Juzina is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise instructed.

The most serious adverse events reported with sitagliptin include pancreatitis, severe allergic reactions such as anaphylaxis, and joint pain. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or unexplained arthralgia.

Juzina is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for individuals with severe renal impairment, as dose adjustment may be required, and for those taking insulin or sulfonylureas without appropriate dose modification.